Leonard Shultz to Graft vs Host Disease
This is a "connection" page, showing publications Leonard Shultz has written about Graft vs Host Disease.
Connection Strength
1.560
-
Brehm MA, Kenney LL, Wiles MV, Low BE, Tisch RM, Burzenski L, Mueller C, Greiner DL, Shultz LD. Lack of acute xenogeneic graft- versus-host disease, but retention of T-cell function following engraftment of human peripheral blood mononuclear cells in NSG mice deficient in MHC class I and II expression. FASEB J. 2019 03; 33(3):3137-3151.
Score: 0.577
-
Pino S, Brehm MA, Covassin-Barberis L, King M, Gott B, Chase TH, Wagner J, Burzenski L, Foreman O, Greiner DL, Shultz LD. Development of novel major histocompatibility complex class I and class II-deficient NOD-SCID IL2R gamma chain knockout mice for modeling human xenogeneic graft-versus-host disease. Methods Mol Biol. 2010; 602:105-17.
Score: 0.313
-
Ono R, Watanabe T, Kawakami E, Iwasaki M, Tomizawa-Murasawa M, Matsuda M, Najima Y, Takagi S, Fujiki S, Sato R, Mochizuki Y, Yoshida H, Sato K, Yabe H, Kato S, Saito Y, Taniguchi S, Shultz LD, Ohara O, Amagai M, Koseki H, Ishikawa F. Co-activation of macrophages and T cells contribute to chronic GVHD in human IL-6 transgenic humanised mouse model. EBioMedicine. 2019 Mar; 41:584-596.
Score: 0.147
-
Ali R, Babad J, Follenzi A, Gebe JA, Brehm MA, Nepom GT, Shultz LD, Greiner DL, DiLorenzo TP. Genetically modified human CD4(+) T cells can be evaluated in?vivo without lethal graft-versus-host disease. Immunology. 2016 08; 148(4):339-51.
Score: 0.123
-
Covassin L, Jangalwe S, Jouvet N, Laning J, Burzenski L, Shultz LD, Brehm MA. Human immune system development and survival of non-obese diabetic (NOD)-scid IL2r?(null) (NSG) mice engrafted with human thymus and autologous haematopoietic stem cells. Clin Exp Immunol. 2013 Dec; 174(3):372-88.
Score: 0.103
-
Covassin L, Laning J, Abdi R, Langevin DL, Phillips NE, Shultz LD, Brehm MA. Human peripheral blood CD4 T cell-engrafted non-obese diabetic-scid IL2r?(null) H2-Ab1 (tm1Gru) Tg (human leucocyte antigen D-related 4) mice: a mouse model of human allogeneic graft-versus-host disease. Clin Exp Immunol. 2011 Nov; 166(2):269-80.
Score: 0.089
-
King MA, Covassin L, Brehm MA, Racki W, Pearson T, Leif J, Laning J, Fodor W, Foreman O, Burzenski L, Chase TH, Gott B, Rossini AA, Bortell R, Shultz LD, Greiner DL. Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex. Clin Exp Immunol. 2009 Jul; 157(1):104-18.
Score: 0.076
-
Turgeon NA, Banuelos SJ, Shultz LD, Lyons BL, Iwakoshi N, Greiner DL, Mordes JP, Rossini AA, Appel MC. Alloimmune injury and rejection of human skin grafts on human peripheral blood lymphocyte-reconstituted non-obese diabetic severe combined immunodeficient beta2-microglobulin-null mice. Exp Biol Med (Maywood). 2003 Oct; 228(9):1096-104.
Score: 0.051
-
Johanna I, Hern?ndez-L?pez P, Heijhuurs S, Bongiovanni L, de Bruin A, Beringer D, van Dooremalen S, Shultz LD, Ishikawa F, Sebestyen Z, Straetemans T, Kuball J. TEG011 persistence averts extramedullary tumor growth without exerting off-target toxicity against healthy tissues in a humanized HLA-A*24:02 transgenic mice. J Leukoc Biol. 2020 06; 107(6):1069-1079.
Score: 0.039
-
Akkina R, Allam A, Balazs AB, Blankson JN, Burnett JC, Casares S, Garcia JV, Hasenkrug KJ, Kashanchi F, Kitchen SG, Klein F, Kumar P, Luster AD, Poluektova LY, Rao M, Sanders-Beer BE, Shultz LD, Zack JA. Improvements and Limitations of Humanized Mouse Models for HIV Research: NIH/NIAID "Meet the Experts" 2015 Workshop Summary. AIDS Res Hum Retroviruses. 2016 Feb; 32(2):109-19.
Score: 0.030
-
Banuelos SJ, Shultz LD, Greiner DL, Burzenski LM, Gott B, Lyons BL, Rossini AA, Appel MC. Rejection of human islets and human HLA-A2.1 transgenic mouse islets by alloreactive human lymphocytes in immunodeficient NOD-scid and NOD-Rag1(null)Prf1(null) mice. Clin Immunol. 2004 Sep; 112(3):273-83.
Score: 0.014